Analysts Hold Neutral Stance on Avantor, Inc. (AVTR) Amid Lower Valuation Expectations

We recently compiled a list of the 10 Best Mid Cap Stocks to Invest In According to Billionaires.  Avantor, Inc. (NYSE:AVTR) is among the best mid cap stocks.

TheFly reported on April 6 that Evercore ISI maintained its In Line rating on AVTR while reducing its price target from $10 to $8.50. The adjustment was made as part of the firm’s broader preview of the medical technology and life sciences tools sector ahead of first-quarter results.

Earlier on April 1, Avantor, Inc. (NYSE:AVTR) announced that its Executive Vice President and Chief Financial Officer, R. Brent Jones, will be departing the company on or before June 24, 2026. In response, the company has begun the process of identifying a permanent successor to fill the CFO role. To maintain continuity during the transition period, Steve Eck, Senior Vice President and Chief Accounting Officer, will step in as interim CFO once Jones leaves.

Eck has been with Avantor since 2019, overseeing financial reporting and internal control functions, and brings extensive prior experience from senior finance positions at several organizations, including CSS Industries, Fidelity National Information Systems, General Electric, and Deloitte & Touche. The company emphasized its focus on ensuring an orderly leadership transition while maintaining stability in its financial operations and reporting structure until a new CFO is appointed.

Avantor, Inc. (NYSE:AVTR) is a global provider of mission-critical products and services to the life sciences, advanced technologies, and applied materials industries. It supplies lab materials, chemicals, and solutions that support research, development, and biopharmaceutical manufacturing.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.